Invesco’s GT Biopharma GTBP Stock Holding History

Invesco’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-433	Closed	-$88K	–	4059
2021 Q3	$88K	Buy	433 +74	+21%	+$22.3K	﹤0.01%	3958
2021 Q2	$167K	Buy	+359	New	+$149K	﹤0.01%	3827

Other funds holding GTBP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Invesco's GTBP Position: Q4 2021 in Review

Invesco sold out of GT Biopharma (GTBP) in Q4 2021, closing a stake of 433 shares — an estimated $88K sold.

Invesco first reported a position in GTBP in Q2 2021 and held it in 2 quarters. The position peaked at $167K in Q2 2021. 53 funds tracked by Wall St. Rank hold GTBP as of Q4 2021.

Invesco reported no remaining GT Biopharma position as of Q4 2021 after selling out during the quarter.
Invesco sold 433 GT Biopharma shares in Q4 2021, an estimated $88K.
Invesco first reported a position in GT Biopharma in Q2 2021 and held it in 2 quarters.
Invesco's GT Biopharma position peaked at $167K in Q2 2021.
53 funds tracked by Wall St. Rank held GT Biopharma as of Q4 2021.

Based on Invesco's 13F filing for Q4 2021, filed 14 Feb 2022.